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Reply 
We appreciate the keen interest of Broka et al. in our work on the 
hemodynamic effects of oxygen. They raised two concerns. The first 
relates to the importance and mechanism of our observation demon- 
strating a diminished cardiac output in response to supplemental 
oxygen. The second relates to the calculated oxygen consumption 
values in our study and the fact that oxygen consumption decreased as 
supplemental oxygen was added. 
With regard to the first concern, the majority of subjects did not 
become symptomatic as we gave supplemental oxygen. However, one 
subject became short of breath and diaphoretic in response to this 
intervention. Another subject who was studied after completing this 
project also became diaphoretic as oxygen was delivered. We did not 
include these data in the original report because we did not systemat- 
ically examine symptoms and considered these data to be too anec- 
dotal. However, as we emphasized in our report, pulmonary capillary 
wedge pressure increased, confirming the finding that oxygen had a 
detrimental hemodynamic effect. We agree that measurements of
plasma lactate would have been useful. Unfortunately, at the time of 
these studies, we did not think of performing these measurements. 
What is the mechanism for the decrease in cardiac output? We 
would expect a change in cardiac output o be associated with either a 
change in loading conditions or a change in inotropy. As mentioned 
above, pulmonary capillary wedge pressure increased in response to 
oxygen, providing evidence that preload increased. This would suggest 
that cardiac output diminished at a time when Starling forces would 
dictate that cardiac output should increase. Therefore, one could only 
conclude that there must be a change in either inotropy or systemic 
resistance. Although we did not measure inotropy directly, a decrease 
in inotropy is typically accompanied by evidence of reflex sympatho- 
excitation. We found no changes in heart rate or peroneal nerve 
muscle sympathetic nervous ystem activity. Thus, we would surmise 
that inotropy did not decrease. We did calculate system vascular 
resistance and found it to increase fairly dramatically. Therefore, our 
data support he contention that oxygen acted as a direct vasoconstric- 
tor, thereby increasing peripheral vascular esistance. 
We have further pursued the issue of changes in systemic resistance 
in our experiments in patients with a left ventricular assist device. We 
have performed studies in six such patients and found a consistent 
relation between increased systemic resistance and the administration 
of oxygen (unpublished observations). Further, in normal subjects, we 
have performed experiments on forearm blood flow in response to 
10 min of forearm ischemia. We have observed that peak vasodilation 
is reduced with the administration of supplemental oxygen (1). The 
exact mechanism for this change in systemic resistance is currently 
unknown, 
In terms of the insightful discussion on oxygen delivery of Broca et 
al., we completely agree that the change in calculated oxygen consump- 
tion in our data would bring into question the dependency of oxygen 
consumption on oxygen delivery. Ideally, one would measure oxygen 
consumption during such experiments. Measuring oxygen consump- 
tion during oxygen delivery is fraught with a number of inaccuracies 
and, accordingly, we did not pursue these measurements. The work 
cited in their letter was performed in anesthetized patients with 
coronary disease (2). These subjects differed considerably from those 
in our study in that they were anesthetized, and there is no comment 
on the presence or absence of congestive heart failure. These are 
important considerations because spontaneous ventilation in the pres- 
ence of increased filling pressures would substantially increase the 
work of breathing and total oxygen consumption. This could substan- 
tially alter the relation between oxygen consumption and oxygen 
delivery so aptly described in your letter. 
With regard to the estimated oxygen consumption values in the 
letter of Broca et al., there were some assumptions made that would 
overestimate he calculated oxygen delivery. In reviewing the data in 
experiment 2,we found that oxygen delivery ranged from 333 ml/min 
on room air to 270 ml/min with 100% oxygen. Accordingly, we were in 
the previously described range where there is a dependency of oxygen 
consumption on oxygen delivery. Additionally, from the data that 
Broca et al. referenced, one would predict a 21% decrease in oxygen 
consumption. Based on our patients, a 29% change was observed. As 
mentioned above, because the patient groups and clinical conditions 
are different, it would be inappropriate o directly apply the previous 
data to our patients. 
In conclusion, our work dealt primarily with the hemodynamic 
effects of supplemental oxygen in conscious humans with severe heart 
failure. We agree with Broca et al. that other "clinical" measures 
during oxygen administration i patients with heart failure are war- 
ranted. 
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Selection Bias in Thrombolytie Trials 
Jha et al. (1) compared the characteristics and mortality outcomes of 
Canadian patients who participated in two thrombolytic trials 
(GUSTO and LATE) with those in patients with acute myocardial 
infarction who did not participate. Administrative discharge data were 
used for nonparticipants o obtain demographic and "comorbidity 
scores." No physiologic data were available for nonparticipants. The 
authors found that trial participants were younger, more likely to be 
male and had a lower comorbidity score. Participants also had lower 
in-hospital mortality "after adjustment for age, gender, revasculariza- 
tion and comorbidity scores." The authors conclude that there is 
selection bias in the recruitment of trial participants, with favoring of 
lower risk patients. 
In essence, what the authors have described are differences in 
demographics, comorbidity scores and mortality between apopulation 
of patients who are eligible for thrombolysis (participants) compared 
with an unselected group of all patients with acute myocardial infarc- 
tion (nonparticipants). Nonparticipants thus include both thrombolysis 
eligible and ineligible patients. It is well known that many patients with 
acute myocardial infarction are ineligible for thrombolysis on the basis 
of late presentation, absence of chest pain, nondiagnostic electrocar- 
diographic findings, uncontrolled hypertension or other contraindica- 
tions (2). Data reveal that these patients are older, more likely to be 
male and more likely to have a higher degree of comorbidity (3). 
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Outcomes among those who are ineligible for thrombolysis worse 
than for those who are eligible and receive thrombolytic agents (2,3). 
Thus, one would expect a mixed group of thrombolysis eligible and 
ineligible patients to be older, more likely to be male and to have a 
higher degree of comorbidity than a group of only thrombolysis eligible 
patients. To conclude that there was true selection bias in the 
recruitment of study participants, one needs to compare the charac- 
teristics of participants with those who were nonparticipants but met 
study criteria for randomization. Because Jha et al. do not have access 
to data that would allow this comparison, they cannot show true 
selection bias. Additionally, observational studies, such as this one, 
which attempt to show outcome differences, must adjust for case mix of 
the different patient groups. The authors duly note that outcome in 
acute myocardial infarction is highly dependent on a number of 
physiologic variables, uch as admission heart rate, blood pressure and 
Killip class. None of these data were available for nonparticipants. In 
the absence of these data, it is difficult to determine whether outcome 
differences occurred due to differences in treatment received or 
because of differences in unmeasured baseline characteristics. 
MARK J. SADA, MD 
Harriman Jones Medical Group 
2600 Redondo Avenue 
Long Beach, California 90806 
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Reply 
In part, Sada simply echoes a caveat hat we presented along with our 
findings, namely, that better characterization f patients would be 
important to explain observed outcome differences (l). We also agree 
that examination ofeligibility for thrombolysis inall participants would 
be the most rigorous way to pin down selection bias. That is where the 
agreement ends. 
Sada would have us believe that thrombolysis eligibility alone 
accounts for the observed ifferences between trial participants and 
nonparticipants. Ironically, one of the references (2) he cites to 
support his argument was actually ameticulous dissection of the extent 
of underutilization f thrombolysis, wherein the authors championed 
the importance of treating elderly patients and those presenting 6 to 
12 h from symptom onset. The second study cited by Sada was by 
Cragg et al. (3). It examined patients presenting to one center between 
1986 and 1988, stated that only 16% of the patients were treated with 
thrombolytics and cited a whole series of now-obsolete criteria as 
reasons for deeming patients ineligible for treatment. Among those 
criteria were age >76 years, presentation >4 h from symptom onset, 
any previous coronary artery, bypass urgery., angioplasty in the pre- 
ceding 2 weeks and left bundle branch block. We are puzzled as to why 
Sada cited this study; but having cited it, he might at least have got the 
authors' message right. Cragg et al. (3) directly challenged the age 
limits on enrollment in thrombolysis trials as likely to cost many lives 
and also wrote: "Apart from the significant age difference, why 
protocol-treated patients had such low-risk characteristics was unclear; 
the inclusion and exclusion criteria did not specifically preclude 
enrollment for patients with many of these high-risk characteristics." 
The evidence for underuse of thrombolytic therapy among elderly 
patients continues to roll in. The most recent study (4) in 11 European 
countries howed that up to 55% of patients with acute myocardial 
infarction were eligible for thrombolysis. However, compared with 
those >65 years old, the odds ratios for use of thrombolysis among 
eligible patients by age bracket were as follows: 65 to 74 years, 0.55 
(95% confidence interval [CI] 0.34 to 0.89); 75 to 84 years, 0.24 (95% 
CI 0.14 to 0.40); and >85 years, 0.04 (95% CI 0.02 to 0.10). 
As our article suggested (4), it seems plausible that arbitrary 
enrollment restrictions in early trials shaped the early perceptions of 
eligibility for thrombolysis, and these biases have continued to influ- 
ence patient selection in both newer trials and ordinary practice. The 
causes, effects and epiphenomena are hard to tease apart; and more 
studies are needed. However, what matters now is optimizing the use 
of thrombolysis around the world and ensuring that any new therapies 
for acute myocardial infarction are tested in a proper spectrum of low 
and high risk patients of all ages. 
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